We are live on ! Find out more
CRVO icon

CervoMed
CRVO

11 hedge funds and large institutions have $590K invested in CervoMed in 2023 Q2 according to their latest regulatory filings, with 0 funds opening new positions, 2 increasing their positions, 4 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

0.83% less ownership

Funds ownership: 6.6% → 5.78% (-0.83%)

8% less funds holding

Funds holding: 12 → 11 (-1)

30% less capital invested

Capital invested by funds: $839K → $590K (-$249K)

50% less repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 4

100% less first-time investments, than exits

New positions opened: 0 | Existing positions closed: 1

Holders
11
Holders Change
-1
Holders Change %
-8.33%
% of All Funds
0.17%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
–
Increased
2
Reduced
4
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Renaissance Technologies
Renaissance Technologies
New York
+$4.65K
2
Wells Fargo
Wells Fargo
California
+$6

Top Sellers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
-$77.6K
2
Vanguard Group
Vanguard Group
Pennsylvania
-$25.3K
3
TRCT
Tower Research Capital (TRC)
New York
-$3.52K
4
UBS Group
UBS Group
Switzerland
-$1.59K
5
Osaic Holdings
Osaic Holdings
Arizona
-$76

CRVO Hedge Fund Activity: Q2 2023 in Review

11 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in CervoMed (CRVO) for Q2 2023, worth a combined $590K — down 30% from $839K a quarter earlier.

Sellers outnumbered buyers: 1 fund closed out of CRVO and 0 opened new positions — a net loss of 1 holder — while 4 trimmed existing stakes and 2 added.

The largest buyer was Renaissance Technologies, adding an estimated $4.65K. The largest seller was Citadel Advisors, exiting entirely with an estimated $77.6K sold.

  • 11 institutional investors held CervoMed (CRVO) as of Q2 2023, down from 12 in Q1 2023.
  • Funds reported $590K of CervoMed stock for Q2 2023, down 30% quarter-over-quarter.
  • 0 funds opened new CervoMed positions in Q2 2023 and 1 closed out, a net change of -1 holder.
  • The largest CervoMed buyer in Q2 2023 was Renaissance Technologies, an estimated $4.65K added.
  • The largest CervoMed seller in Q2 2023 was Citadel Advisors, an estimated $77.6K sold.

Based on aggregated 13F filings for Q2 2023.